ArticlePloS one2025
Anti-arthritic and endothelial protective effects of Derris scandens extract in adjuvant-induced arthritis in rats.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis is a chronic inflammatory disease associated with a significantly increased risk of cardiovascular mortality. This study investigated the therapeutic potential of Derris scandens (Roxb.) Benth. stem extract (DS) in mitigating vascular and cardiac damage associated with arthritis in an adjuvant-induced arthritis (AIA) rat model. Treatment with DS (200 mg/kg/day, p.o.), methotrexate (1 mg/kg/week, s.c.), or their combination was administered post-induction from day 11-32. Body weight, arthritis scores, and paw diameters were monitored daily. At the end of the treatment period, electrocardiographic parameters and blood pressure were assessed in anesthetized rats. Endothelial function was evaluated in isolated pulmonary arteries (PA) and aortae via acetylcholine-induced relaxation. Plasma inflammatory cytokines were quantified, and leukocyte populations were analyzed in blood and PA tissues. The direct vascular effects of DS were also examined in healthy rats. Direct exposure to DS induced greater relaxation in the PA (Emax = 90%) than in the aorta (Emax = 38%). When administered to arthritic rats, DS significantly reduced arthritis scores and paw diameters compared to untreated rats. Furthermore, DS markedly improved endothelial function in both the PA and aorta, in conjunction with reductions in plasma levels of TNF-α and IL-1β, as well as a decrease in leukocyte populations, particularly neutrophils. However, co-administration with methotrexate attenuated the vascular effects. No significant changes were observed in body weight, electrocardiographic parameters, or blood pressure across treatment groups. This study highlights the potential of DS in improving endothelial function and in mitigating arthritis-related inflammation. Our data also supports the role of vascular neutrophil infiltration in the manifestation of endothelial dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.